Pharmaceutical News and Articles

Comprehensive and up-to-date drug news for both consumers and healthcare professionals.

Judge Declares Wyoming's Abortion Bans Unconstitutional

Two Wyoming abortion bans, including the first state law to prohibit the use of abortion pills, violate the state s constitution, a judge ruled Monday. In her d

Icotrokinra Delivered an Industry-Leading Combination of Significant Skin Clearance with Demonstrated Tolerability in a Once Daily Pill in Phase 3 Topline Results

SPRING HOUSE, Pa. (November 18, 2024) Johnson Johnson (NYSE JNJ) today announced positive topline results from ICONIC-LEADa, a pivotal Phase 3 investigational s

Gabapentinoid Use Tied to Higher Risk for Hip Fractures

Gabapentinoid use is associated with an increased risk for hip fractures, according to a study published online Nov. 13 in JAMA Network Open.Miriam T.Y. Leung,

Metformin Use Tied to Lower Rate of Asthma Attacks

Metformin is associated with a lower rate of asthma attacks among people with diabetes, according to a study published online Nov. 18 in JAMA Internal Medicine.

Primary Care Encounter Notes Often Lack Thoroughness

Physician electronic health record (EHR) notes of primary care patient encounters often lack thoroughness, according to a study recently published online in BMC

Transcranial Direct Current Stimulation Safe, Effective for Tardive Dyskinesia

Transcranial direct current stimulation (tDCS) may be an effective and safe treatment for improving the facial-oral motor symptoms of tardive dyskinesia (TD) in

Global Coverage With Measles Vaccine Declined During COVID-19

Global coverage with measles vaccination declined during the COVID-19 pandemic, and estimated measles cases increased 20 percent worldwide from 2022 to 2023, ac

Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran

PASADENA, Calif. (BUSINESS WIRE) Nov. 18, 2024 Arrowhead Pharmaceuticals, Inc. (NASDAQ ARWR) today announced new results from the Phase 3 PALISADE study and the

Muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose

INDIANAPOLIS, Nov. 18, 2024. Eli Lilly and Company today announced positive Phase 2 results for muvalaplin, an investigational once-daily, orally administered s

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

PALO ALTO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) BridgeBio Pharma, Inc. (Nasdaq BBIO) ( BridgeBio or the Company ), a new type of biopharmaceutical company foc

Popular Keywords